title: Normal outcome of pregnancy with ongoing treatment with natalizumab.
abstract: BACKGROUND
  Treatment of multiple sclerosis (MS) with natalizumab during pregnancy is not recommended due to potential risks for the foetus. Despite strong advice accidental pregnancies occur.
  
  
  METHODS
  A 32-year old woman with MS since the age of 26 was treated with natalizumab since January 2008. Treatment was stopped April 2011 due to pregnancy plans, but was restarted following an MS relapse. The patient was thoroughly informed about potential foetal risks, but nevertheless she one year later disclosed that she was pregnant in gestational week 15. Treatment was continued, since the first trimester had passed. The pregnancy course was normal and a healthy daughter was born at full gestational term.
  
  
  CONCLUSIONS
  This is the second known case where natalizumab treatment continued throughout the whole gestational period.
authors: Department of Neuroscience/Neurology, Uppsala University, Uppsala, Sweden; Department of Neurology, University Hospital, Uppsala, Sweden.
authors: J
authors: J
authors: Fagius
authors: J
authors: J
authors: Burman
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab
keywords: multiple sclerosis; natalizumab; pregnancy; teratogenecity